Locatim (Serinucoli) (Bovine concentrated lactoserum containing...) - QI02AT01

Updated on site: 20-Sep-2017

Medication name: Locatim (Serinucoli)
ATC: QI02AT01
Substance: Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin
Manufacturer: Biokema Anstalt

What benefit has Locatim shown during the studies?

In the laboratory-based study, calves receiving Locatim had less severe clinical signs of diarrhoea and better survival time than those that did not receive it. These results were confirmed in a field-based study.

What is the risk associated with Locatim?

There are no major side effects with Locatim.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

There are no special precautions for Locatim.

What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?

The withdrawal period is zero days.

Why has Locatim been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Locatim exceed the risks for the treatment of calves less than 12 hours of age to reduce mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam, and recommended that Locatim be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.

Other information about Locatim:

The European Commission granted a marketing authorisation valid throughout the European Union for Serinucoli to Biokema Anstalt on 29 March 1999. The name of the medicine was changed to Locatim on 14 September 1999. The marketing authorisation was renewed on 29 March 2004. Information on the prescription status of this product may be found on the label/outer package.

This summary was last updated in September 2007.

EMEA 2007

Comments